Navigation Links
Medication may prevent depression in patients with head and neck cancer
Date:5/19/2008

Taking the antidepressant citalopram before beginning treatment for head and neck cancer may help prevent depression during therapy, according to results of a pilot study published in the May issue of Archives of OtolaryngologyHead & Neck Surgery, one of the JAMA/Archives journals.

Treatment for head and neck cancer can be arduous and debilitating, the authors write as background information in the article. Psychiatric morbidity in these patients is frequent and underdiagnosed. Major depressive disorder has been reported in up to 40 percent of patients with head and neck cancer, typically within the first three months of diagnosis.

William M. Lydiatt, M.D., of the University of Nebraska Medical Center and Nebraska Methodist Hospital, Omaha, and colleagues conducted a randomized clinical trial involving patients with head and neck cancer. Before beginning treatment, 15 participants were randomly assigned to receive 40 milligrams of the antidepressant citalopram daily and 13 were randomly assigned to take placebo. The patients took the medications for 12 weeks, during which time they underwent cancer treatment and were screened for depression every four weeks. Twenty-two patients were assessed at week 12, and 23 patients completed a final study visit four weeks after stopping the medication.

The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were five of 10 (50 percent) taking placebo and two of 12 (17 percent) taking citalopram, the authors write. No patients in the citalopram group became suicidal, compared with two in the placebo group. Quality of life, as measured by a self-administered questionnaire, deteriorated in both groups during treatment but less so in the group taking citalopram.

The data from this pilot trial suggest that prevention of major depressive disorder in patients undergoing treatment for head and neck cancer may be an attainable goal. The data show trends toward major depressive disorder prevention in this small sample. All measures of psychiatric well-being favored the group taking citalopram, the authors conclude. This study suggests a tangible means to improve outcome in patients with head and neck cancer and supports additional research toward this aim.


'/>"/>

Contact: Vicky Cerino
402-559-5190
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD
2. Migraine Medications May Cause Serotonin Syndrome
3. Chronic Medication Nation: Research Finds Chronic Health Problems Now Afflict More Than Half of All Americans
4. Nations First of its Kind Consumer Medication Return Initiative Creates Momentum for Safe Drug Disposal in the U.S.
5. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
6. Self-Medication One of Many Factors Driving OTC Drug Market Past $80 Billion by 2012
7. Quarter of Disabled Seniors Use Risky Medications
8. CNS Response, Inc.: Poster Session on Referenced-EEG Guided Medication to Be Presented at the American Psychiatric Association 161st Annual Meeting
9. Common Medications Could Cause Physical Impairment in the Elderly
10. Commonly used medications associated with impaired physical function in older adults
11. 1 in 10 children using cough, cold medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... property taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, ... many overseas retirement havens have extremely low property-tax rates, which contributes to the ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
Breaking Medicine Technology: